Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...

Ex-MLB star Paul Lo Duca just revealed he was in a bad accident recently ... one that left him with several broken bones.

A Bay of Plenty retiree is in a “hell of a fight” with the Accident Compensation Corporation (ACC) for compensation after his terminal cancer diagnosis was delayed by 19 months.

An ‘all clear’ at the end of treatment doesn’t necessarily mean the end of cancer. But new UK research aims to eliminate the ...

A Bay of Plenty retiree is in a “hell of a fight” with the Accident Compensation Corporation (ACC) for compensation after his ...

After snapping a few photos, some of which included their goldendoodle who wore a handkerchief that read, “Mint to be,” ...

Access the Mets beat like never before Join Post Sports+ for exciting subscriber-only features, including real-time texting ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

Aston University is collaborating in research to develop an injectable paste which could treat bone cancer.

Aston University is collaborating in research to develop an injectable paste which could treat bone cancer. The Royal ...

The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.